Dr. James L. Wade III, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 336
Licensed in Illinois since 1979, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
IL license 036059192 (first issued 1979; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 336
- Services billed
- 109,778
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, nivolumab, 1 mg | 37,300 | 12 |
| Injection, pembrolizumab, 1 mg | 26,300 | 23 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 16,000 | 89 |
| Injection, aprepitant, 1 mg | 11,830 | 23 |
| Injection, paclitaxel, 1 mg | 10,341 | 13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 4,224 | 61 |
| Injection, palonosetron hcl, 25 mcg | 2,190 | 41 |
| Injection, ondansetron hydrochloride, per 1 mg | 2,036 | 34 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,638 | 373 |
| Injection of additional new drug or substance into vein | 1,560 | 72 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Decatur, IL | 162 |
| Prednisone Other prescribers in Decatur, IL | 90 |
| Prochlorperazine Maleate Other prescribers in Decatur, IL | 59 |
| Abiraterone Acetate | 44 |
| Ondansetron Odt (ondansetron) Other prescribers in Decatur, IL | 39 |
| Ondansetron Hcl Other prescribers in Decatur, IL | 38 |
| Alprazolam Other prescribers in Decatur, IL | 37 |
| Letrozole Other prescribers in Decatur, IL | 31 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Decatur, IL | 28 |
| Allopurinol Other prescribers in Decatur, IL | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 5 payments worth $292 in total to this clinician.
| Pfizer Inc. | $175 |
|---|---|
| Fennec Pharmaceuticals, Inc. | $55.25 |
| Abbott Laboratories | $21.71 |
| EMD Serono, Inc. | $20.70 |
| Amneal Pharmaceuticals LLC | $18.93 |
| Consulting Fee | $175 |
|---|---|
| Food and Beverage | $117 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jul 2, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $175 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 20 industry-funded studies in 2025, from 8 companies. The companies reported $508,076 in research payments for these studies, mostly to the institutions running them.
- A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non …
AstraZeneca Pharmaceuticals LP - A phase 3 randomized doubleblind placebocontrolled study of mevrometostat PF06821497 with enzalutamide in metastatic castrationsensitive prostate cancer MEVPRO3
Pfizer Inc. - Study name not reported
Pfizer Inc. - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer
AstraZeneca Pharmaceuticals LP - A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)
Janssen Research & Development, LLC - A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inopera…
E.r. Squibb & Sons, L.l.c. - A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously …
Celgene Corporation - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - BNT000-001
BioNTech SE
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.